Development of a New Combination Platform for the Early Screening of Gastric Cancer Using Serum Biomarkers

A B S T R A C T

Objective: The combination of pepsinogens (PG I/II) and gastrin-17 (G17) has been used to screen GC in many countries, without satisfactory levels of sensitivity or specificity. The aim of this study was to find a better marker and a new modality in screening early GC.
Methods: We measured the serum levels of PG I/II, G17, and prealbumin (PA) from the serum of 481 healthy individuals, 407 benign gastric diseases (BGD), and 416 GC patients using a latex particle-enhanced turbidimetric immunoassay and Sandwich ELISA. Logistic regression analysis was used to obtain the sensitivity and specificity of the combined detection model.
Results: When PA was combined with the other biomarkers, the sensitivity and specificity were significantly improved in the ROC curve. The combination of PA+G17+PGI+PGR was the best diagnostic combination for both early and late GC. The AUC, sensitivity, and specificity of the combination for discriminating between early GC and healthy individuals were 0.796, 72.1% and 74.2% respectively. For distinguishing patients with early GC from BGD, the AUC, sensitivity and specificity of the combination were 0.696, 66.7% and 65.4%, respectively. The combination of PA+G17+PGI+PGR improved both the sensitivity and the specificity of GC diagnosis compared with those of the traditional combination of G17+PGI+ PGII +PGR.
Conclusion: PA is a valuable indicator for GC and interacts synergistically with PG and G17 in screening for early GC. The new combination platform PA+G17+PGI+PGR may be a potential way for the early screening of GC.

Keywords

Combination platform, early screening, PA, PG, G17, gastric cancer

Get access to the full version of this article.

Article Info

Article Type

Research Article

Publication history

Received: Thu 22, Apr 2021
Accepted: Sat 08, May 2021
Published: Thu 27, May 2021

Copyright

© 2023 Weiqun Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2021.05.05

Author Info

Limin Ding Honglang Li Guoxing Xie Weiqun Rao Jiquan Yu Yanjiao Du Wei Tang Yuefei Yu

Corresponding Author

Weiqun Rao
Department of Orthopedics, Dongxiang District People’s Hospital, Fuzhou, Jiangxi, China

Figures & Tables

Get access to the full version of this article.

References

1.     Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424. [Crossref]

2.     Rawla P, Barsouk A (2019) Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 14: 26-38. [Crossref]

3.     Dai M, Shi J, Li N (2013) The design and Aim of Cancer Screening Programme in Urban China. Zhonghua Yu Fang Yi Xue Za Zhi 47: 179-182.

4.     You W (2009) Progress in Early Detection and Treatment for Gastric Cancer. Zhongguo Zhong Liu 18: 695-699.

5.     Zong L, Abe M, Seto Y, Ji J (2016) The challenge of screening for early gastric cancer in China. Lancet 388: 2606. [Crossref]

6.     Parthasarathy G, Maroju NK, Kate V, Ananthakrishnan N, Sridhar MG (2007) Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. Trop Gastroenterol 28: 166-170. [Crossref]

7.     Wang Y, Zhu Z, Liu Z, Zhao Z, Xue X et al. (2020) Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer. J Int Med Res 48: 300060520914826. [Crossref]

8.     Cho JH, Jeon SR, Kim HG, Jin SY, Park S (2017) The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea. Medicine (Baltimore) 96: e7603. [Crossref]

9.     Abraham A, Girish TU, Sharathchandra BJ, Madhunapantula SV, Yadav MK et al. (2017) Serum pepsinogen I and pepsinogen II levels and its ratio in patients with gastric cancer: a case control study. Int Surg J 4: 356.

10.  Zheng W, Lu YM, Lu GY, Zhao Q, Cheung O et al. (2001) Transthyretin, thyroxine, and retinol-binding protein in human cerebrospinal fluid: effect of lead exposure. Toxicol Sci 61: 107-114. [Crossref]

11.  Schweigert FJ, Sehouli J (2005) Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res 65: 1114. [Crossref]

12.  Wang M, Wang J, Jiang H (2019) Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer. Oncol Lett 17: 3227-3232. [Crossref]

13.  Shimura T, Shibata M, Gonda K, Okayama H, Saito M et al. (2018) Serum transthyretin level is associated with prognosis of patients with gastric cancer. J Surg Res 227: 145-150. [Crossref]

14.  Zu H, Wang H, Li C, Xue Y (2020) Preoperative prealbumin levels on admission as an independent predictive factor in patients with gastric cancer. Medicine (Baltimore) 99: e19196. [Crossref]

15.  Miftahussurur M, Waskito LA, Aftab H, Vilaichone RK, Subsomwong P et al. (2020) Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations. PLoS One 15: e0230064. [Crossref]

16.  Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X et al. (2015) Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One 10: e0142080. [Crossref]

17.  Kim N, Jung HC (2010) The role of serum pepsinogen in the detection of gastric cancer. Gut Liver 4: 307-319. [Crossref]

18.  Cao XY, Jia ZF, Jin MS, Cao DH, Kong F et al. (2012) Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol 18: 7357-7361. [Crossref]

19.  Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y et al. (2006) The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 163: 629-637. [Crossref]

20.  Kikuchi R, Abe Y, Iijima K, Koike T, Ara N et al. (2011) Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med 223: 35-44. [Crossref]

21.  Copps J, Murphy RF, Lovas S (2009) The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers. Protein Pept Lett 16: 1504-1518. [Crossref]

22.  Shafaghi A, Mansour Ghanaei F, Joukar F, Sharafkhah M, Mesbah A et al. (2013) Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions. Asian Pac J Cancer Prev 14: 3931-3936. [Crossref]

23.  Ingenbleek Y (2018) The Retinol Circulating Complex Releases Hormonal Ligands During Acute Stress Disorders. Front Endocrinol (Lausanne) 9: 487. [Crossref]

24.  Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters. Cell Mol Life Sci 66: 3095-3101. [Crossref]

25.  Liu L, Liu J, Dai S, Wang X, Wu S et al. (2007) Reduced transthyretin expression in sera of lung cancer. Cancer Sci 98: 1617-1624. [Crossref]

26.  Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A et al. (2009) Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 12: 158-163. [Crossref]

27.  Yu Z, Ji M, Yang X, Zhang S, Huang X et al. (2008) Serum pepsinogen detection in gastric cancer screening. Chin J Digest Endosc 25: 512-515.

28.  Aoki K, Misumi J, Kimura T, Zhao W, Xie T (1997) Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen I, II and of PG I/PG II ratios in a gastric cancer case-control study. J Epidemiol 7: 143-151. [Crossref]